Intravenous xenon- 133 for the determination of radionuclide first pass right ventricular ejection fraction.
The use of intravenous xenon- 133 for determination of radionuclide first pass right ventricular ejection fraction is described. First pass determinations of right ventricular ejection fraction were made with both xenon- 133 and technetium-99m in 13 subjects (15 right ventricular ejection fraction determinations); results obtained with xenon- 133 show an excellent correlation (r = 0.98, p less than 0.002) with results obtained using technetium-99m. Because of rapid pulmonary elimination of xenon- 133 from the body, the use of this radioisotope allows multiple first pass right ventricular ejection fraction determinations within a short period of time, without significant radiation exposure for the patient.
D000208:Acute Disease; D000787:Angina Pectoris / Q000000981:diagnostic imaging; D002908:Chronic Disease; D003327:Coronary Disease / Q000000981:diagnostic imaging; D006333:Heart Failure; D006352:Heart Ventricles / Q000000981:diagnostic imaging*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000000981:diagnostic imaging; D008173:Lung Diseases, Obstructive / Q000000981:diagnostic imaging; D009203:Myocardial Infarction / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D013667:Technetium; D014980:Xenon Radioisotopes
D014980:Xenon Radioisotopes; D013667:Technetium